Baird analyst Eric Coldwell has adjusted the price target for Medpace Holdings (MEDP, Financial), reducing it from $340 to $313. This revision follows the company's first-quarter financial performance. While the firm remains neutral about the shares, there is a cautious stance due to bookings that are still in a "show-me" phase, indicating a need for further evidence of sustained growth or improvement.
The neutral rating reflects a balanced view of MEDP stock, neither overly optimistic nor pessimistic, suggesting that there's potential for movement in either direction depending on future company developments.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 10 analysts, the average target price for Medpace Holdings Inc (MEDP, Financial) is $312.93 with a high estimate of $404.00 and a low estimate of $280.00. The average target implies an upside of 10.86% from the current price of $282.28. More detailed estimate data can be found on the Medpace Holdings Inc (MEDP) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Medpace Holdings Inc's (MEDP, Financial) average brokerage recommendation is currently 2.8, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Medpace Holdings Inc (MEDP, Financial) in one year is $365.69, suggesting a upside of 29.55% from the current price of $282.28. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Medpace Holdings Inc (MEDP) Summary page.
